ISH 2022 | Kinase domain mutation screening in patients with Ph+ ALL and CML
Josep-Maria Ribera
• 8 Oct 2022
Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, explains the importance of kinase domain mutation screening in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) where the frequency of mutations differs substantially. The evolution of mutations as the disease progresses is key to making therapeutic decisions. This interview took place at the 38th World Congress of the International Society of Hematology 2022.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
